Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Größe/SKU | Verfügbarkeit | Preis |
|---|
Über diesen Artikel
Empirische Formel (Hill-System):
C36H40ClN9O5S
CAS-Nummer:
Molekulargewicht:
746.28
UNSPSC Code:
12352200
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCCNC(COC5=CC=C(C=C5)C6CCC(NC6=O)=O)=O)=N1
InChI key
AJNQGWOQPRWRML-UHFFFAOYSA-N
Biochem/physiol Actions
Potent ABL and SRC family tyrosine kinases (TYKs) degrader with greater antileukemic efficacy than dasatinib in cultures and in vivo.
SJ11646 is a potent and high-affinity (LCK/ABL1/SRC Kd = 0.14/0.054/0.17 nM for SJ11646 vs. 0.09/0.054/0.19 nM for dasatinib) ABL and SRC family tyrosine kinases (TYKs) degrader composed of dasatinib linked to a E3 ligase cereblon (CRBN)-binding ligand. SJ11646 effectively degrades SRC family TYKs in KOPT-K1 cells (LCK, CSK, SRC, FYN; 100 nM for 24h) and is 55,114-times more cytotoxic (LC50 = 0.0123 pM) than dasatinib against the BCR-ABL fusion-harboring B-ALL cell line SUP-B15. When used at equal molar amount via daily i.p., SJ11646 (15 mg/kg) shows significantly greater antileukemic efficacy than dasatinib (10 mg/kg) in two T-ALL PDX models in mice in vivo.
SJ11646 is a potent and high-affinity (LCK/ABL1/SRC Kd = 0.14/0.054/0.17 nM for SJ11646 vs. 0.09/0.054/0.19 nM for dasatinib) ABL and SRC family tyrosine kinases (TYKs) degrader composed of dasatinib linked to a E3 ligase cereblon (CRBN)-binding ligand. SJ11646 effectively degrades SRC family TYKs in KOPT-K1 cells (LCK, CSK, SRC, FYN; 100 nM for 24h) and is 55,114-times more cytotoxic (LC50 = 0.0123 pM) than dasatinib against the BCR-ABL fusion-harboring B-ALL cell line SUP-B15. When used at equal molar amount via daily i.p., SJ11646 (15 mg/kg) shows significantly greater antileukemic efficacy than dasatinib (10 mg/kg) in two T-ALL PDX models in mice in vivo.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| description ≥98% (HPLC) | description ≥98% (HPLC) | description United States Pharmacopeia (USP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay - | assay - |
| form powder | form powder | form - | form powder |
| Quality Level 100 | Quality Level - | Quality Level - | Quality Level - |
| storage temp. -10 to -25°C | storage temp. −20°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: 2 mg/mL, clear | solubility DMSO: 2 mg/mL, clear | solubility - | solubility - |
| color white to beige | color white to beige | color - | color - |
Lagerklasse
11 - Combustible Solids
Was ist los?
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.


